Gavin Giovannoni
Gavin Giovannoni
Barts and The London School of Medicine and Dentistry
giovannoni.net üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ...
New England Journal of Medicine 354 (9), 899-910, 2006
31022006
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
13332012
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution
SV Ramagopalan, A Heger, AJ Berlanga, NJ Maugeri, MR Lincoln, ...
Genome research 20 (10), 1352-1360, 2010
8432010
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...
The Lancet 380 (9856), 1819-1828, 2012
8352012
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New England Journal of Medicine 376 (3), 209-220, 2017
7432017
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ...
New England Journal of Medicine 362 (5), 416-426, 2010
6712010
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
G Giovannoni, JD O'sullivan, K Turner, AJ Manson, AJL Lees
Journal of Neurology, Neurosurgery & Psychiatry 68 (4), 423-428, 2000
6402000
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
6352017
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
DB Clifford, A DeLuca, DM Simpson, G Arendt, G Giovannoni, A Nath
The Lancet Neurology 9 (4), 438-446, 2010
6332010
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity
RB Banati, J Newcombe, RN Gunn, A Cagnin, F Turkheimer, F Heppner, ...
Brain 123 (11), 2321-2337, 2000
6292000
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
AJ Noyce, JP Bestwick, L Silveira‐Moriyama, CH Hawkes, G Giovannoni, ...
Annals of neurology 72 (6), 893-901, 2012
5212012
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement
MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ...
Archives of neurology 62 (6), 865-870, 2005
5212005
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
SV Ramagopalan, R Dobson, UC Meier, G Giovannoni
The Lancet Neurology 9 (7), 727-739, 2010
5182010
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing …
E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ...
The Lancet Neurology 8 (3), 254-260, 2009
4452009
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
CE Teunissen, A Petzold, JL Bennett, FS Berven, L Brundin, M Comabella, ...
Neurology 73 (22), 1914-1922, 2009
4282009
The therapeutic potential of cannabis
D Baker, G Pryce, G Giovannoni, AJ Thompson
The Lancet Neurology 2 (5), 291-298, 2003
4252003
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
G Pryce, Z Ahmed, DJR Hankey, SJ Jackson, JL Croxford, JM Pocock, ...
Brain 126 (10), 2191-2202, 2003
3672003
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL
PA Calabresi, G Giovannoni, C Confavreux, SL Galetta, E Havrdova, ...
Neurology 69 (14), 1391-1403, 2007
3362007
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB 1 on neurons and CB 2 on autoreactive T cells
K Maresz, G Pryce, ED Ponomarev, G Marsicano, JL Croxford, LP Shriver, ...
Nature medicine 13 (4), 492-497, 2007
3362007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
DH Miller, D Soon, KT Fernando, DG MacManus, GJ Barker, TA Yousry, ...
Neurology 68 (17), 1390-1401, 2007
3262007
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20